FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

6 results

columvi
(Glofitamab)
Genentech, Inc.
Usage: COLUMVI is indicated for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL, NOS) or large B-cell lymphoma from follicular lymphoma, following two or more lines of systemic therapy. This indication is granted under accelerated approval, pending further confirmation of clinical benefit.
epkinly
(epcoritamab-bysp)
Genmab US, Inc.
Usage: EPKINLY is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma after two or more systemic therapies, as well as for relapsed or refractory follicular lymphoma (FL) after similar treatment. Approval is based on response rates and durability.
polivy
(polatuzumab vedotin)
Genentech, Inc.
Usage: POLIVY is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL), and for those with relapsed or refractory DLBCL, NOS, after at least two prior therapies, in combination with specific regimens.
rituxan hycela
(rituximab and hyaluronidase)
Genentech, Inc.
Usage: RITUXAN HYCELA is indicated for adult patients with relapsed/refractory and previously untreated follicular lymphoma, as maintenance therapy or after CVP chemotherapy. It treats diffuse large B-cell lymphoma in combination with CHOP, and chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Not for non-malignant conditions.
ruxience
(rituximab-pvvr)
Pfizer Laboratories Div Pfizer Inc
Usage: RUXIENCE is indicated for adult patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis and microscopic polyangiitis, often in combination with other therapies, depending on the specific condition and patient response.
xpovio
(selinexor)
Karyopharm Therapeutics Inc.
Usage: XPOVIO is indicated for adults with multiple myeloma who have had prior therapy, in combination with bortezomib and dexamethasone, or dexamethasone alone for heavily pretreated patients. It is also approved for relapsed or refractory diffuse large B-cell lymphoma after at least two systemic therapies.

Medications for Diffuse Large Bcell Lymphoma

columvi

epkinly

polivy

rituxan hycela

ruxience

xpovio